Linda Neckmar is proposed as a new board member of EQL Pharma AB for election at the Annual General Meeting on 27 August 2020

Linda Neckar (born 1973) has 25 years of experience from Healthcare and Pharmaceutical industry, in both small and larger companies, where she has held leading positions in scientific business development, marketing and sales, contract negotiation and project management.

From 2011 to 2020, Linda was employed at Probi AB, where she worked with marketing and sales, acquisitions, and operations, for a number of years in the executive management team. Earlier in her career, Linda was employed as a business developer at Bioinvent, where she signed technology licensing agreements with Bayer and Misubishi Tababe Pharma.

Linda is employed by Chr Hansen A/S since 2020 with global responsibility for Commercial Development of the Human Health organization.

Since 2017, Linda also works as a board member in several companies in life science. She holds a Master of Science degree in chemical engineering from Lund Institute of Technology.

"We welcome Linda as a new member of the Board. Her background is very relevant and matches EQL's needs during the company's growth journey," said Christer Fåhraeus, Chairman of the Nomination Committee.

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00

EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 18 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2020 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 9 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.


Documents & Links